correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression. [ Time Frame: 7 years ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples With DNA

Blutsample

Enrollment:

144

Study Start Date:

January 2010

Study Completion Date:

May 2014

Primary Completion Date:

May 2014 (Final data collection date for primary outcome measure)

Detailed Description:

correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

Eligibility

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

patients who underwent organ transplatation or patients who have a HIV infection

Criteria

Inclusion Criteria:

patients in an immunosuppressive condition either by immunosuppressants or by HIV infection

Exclusion Criteria:

written informed consent not given

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01942005